PAVmed Inc. (NASDAQ:PAVM) Short Interest Up 161.8% in January

PAVmed Inc. (NASDAQ:PAVM) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 129,582 shares, a growth of 161.8% from the January 15th total of 49,495 shares. Currently, 14.5% of the shares of the stock are short sold. Based on an average daily volume of 5,566,555 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 5,566,555 shares, the short-interest ratio is currently 0.0 days. Currently, 14.5% of the shares of the stock are short sold.

Institutional Investors Weigh In On PAVmed

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC boosted its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the quarter. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.93% of the company’s stock.

PAVmed Stock Down 4.4%

Shares of PAVM traded down $0.45 during trading on Friday, reaching $9.83. 31,297 shares of the company traded hands, compared to its average volume of 2,047,572. The stock has a 50-day simple moving average of $8.96 and a 200-day simple moving average of $11.62. The stock has a market cap of $9.63 million, a PE ratio of -0.57 and a beta of 1.12. PAVmed has a twelve month low of $6.00 and a twelve month high of $28.44.

Analyst Ratings Changes

A number of brokerages have recently commented on PAVM. Zacks Research cut shares of PAVmed from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a report on Thursday, January 22nd. Finally, Ascendiant Capital Markets lowered their price objective on PAVmed from $600.00 to $510.00 and set a “buy” rating on the stock in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, PAVmed has an average rating of “Hold” and an average target price of $510.00.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.